LifeNet Health features best-in-class orthobiologic solutions at AAOS Annual Meeting
LifeNet Health features best-in-class orthobiologic solutions at AAOS Annual Meeting
SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- LifeNet Health, the world's leading provider of allograft biologics, is showcasing its comprehensive portfolio of advanced biomaterials at the 2021 AAOS Annual Meeting (Booth #1527) Sept. 1-3.
聖迭戈，2021年8月31日/美通社/--世界領先的同種異體移植生物製品供應商LifeNet Health將在2021年AAOS年會(展位#1527)上展示其先進生物材料的全面產品組合。1比3。
Its featured solutions include ViviGen® Cellular Bone Matrix, the first and only osteobiologic designed to recover and maintain lineage-committed bone cells; ArthroFlex® SCR acellular dermal matrix, the gold standard for superior capsular reconstruction; and FlexiGraft® QuadLink™, the only pre-sutured quadriceps tendon for ACL reconstruction.
其特色解決方案包括VIviGen®細胞骨基質，這是第一個也是唯一一個旨在恢復和維持骨系細胞的骨生物學；ArthroFlex®SCR脱細胞真皮基質，高級包膜重建的黃金標準；以及Flexigraft®Quadlink™，唯一用於前交叉韌帶重建的預先縫合的股四頭肌腱。
"Our portfolio reflects close collaboration with clinicians to understand the challenges they face in helping their patients heal," said Daniel Osborne, LifeNet Health Vice President of Global Marketing and Commercial Strategy. "Combined with our unique technologies, this insight enables LifeNet Health to make better biologics that are uniquely engineered to address those challenges, and the data being shared at AAOS shows that's precisely what they do."
LifeNet Health負責全球營銷和商業戰略的副總裁丹尼爾·奧斯本(Daniel Osborne)説：“我們的產品組合反映了與臨牀醫生的密切合作，以瞭解他們在幫助患者康復方面面臨的挑戰。與我們獨特的技術結合在一起，這種洞察力使LifeNet Health能夠製造出更好的生物製品，這些生物製品是為應對這些挑戰而獨特設計的，AAOS分享的數據表明，這正是他們所做的。“
Live Presentations — In-Person or Online
In addition to its exhibit hall and digital presence, LifeNet Health's AAOS activities include live programming to provide the latest clinical and economic data about its world-class biologics.
現場演示-面對面或在線
除了展廳和數字展示，LifeNet Health的AAOS活動還包括現場編程，以提供有關其世界級生物製劑的最新臨牀和經濟數據。
Elena Gianulis, PhD, LifeNet Health's Medical Science Liaison, will lead two in-booth presentations on two of the most-advanced allograft bone-healing solutions available, ViviGen and PliaFX® Prime. The first session explores the growing body of evidence showing ViviGen supports healing in trauma, extremity and spine procedures, including recent studies that showed ViviGen supports outcomes equivalent to autograft1,2 and superior to mesenchymal stem cell (MSC)-based grafts in even high-risk foot and ankle procedures.
LifeNet Health醫學科學聯絡人Elena Gianulis博士將主持兩場關於ViviGen和Paria FX®Prime這兩種最先進的同種異體骨癒合解決方案的展位演講。第一部分探討了越來越多的證據表明ViviGen支持創傷、四肢和脊柱手術的癒合，包括最近的研究表明ViviGen支持等同於自體移植的結果1,2甚至在高危足踝手術中也優於以間充質幹細胞(MSC)為基礎的移植物。
The second session will focus on how the unique technology of PliaFX Prime 100% bone moldable demineralized fibers supports effective clinical outcomes while providing exceptional value to hospitals. The presentations take place at 3:10 p.m. PDT Sept. 1 and Sept. 2 and will be streamed live to LifeNet Health's online showcase.
第二場會議將重點介紹Paria FX Prime 100%骨可模塑脱鈣纖維的獨特技術如何在為醫院提供非凡價值的同時，支持有效的臨牀結果。演講將於下午3點10分舉行。PDT9月1.和9月1日。2，並將在LifeNet Health的在線展示中進行現場直播。
AAOS-Hosted Innovation Theater Sessions
Two surgeons will present at AAOS Innovation Theater sessions about their experience using ViviGen and the results it is providing for their patients.
AAOS主辦的創新劇院會議
兩名外科醫生將在AAOS創新劇院會議上介紹他們使用ViviGen的經驗以及它為他們的患者提供的結果。
Richard Yoon, MD, director of Orthopedic Research in the Division of Orthopedic Trauma and Adult Reconstruction at Jersey City Medical Center, will describe his use of ViviGen in a series of challenging trauma cases. He also will discuss the 500-patient trauma registry he is leading that will collect data at seven Level 1 trauma centers to describe both the safety and efficacy of ViviGen.
澤西市醫療中心整形外科創傷和成人重建部整形外科研究主任Richard Yoon醫學博士將介紹他在一系列具有挑戰性的創傷案例中使用ViviGen的情況。他還將討論他領導的500名患者的創傷登記，該登記將在7個一級創傷中心收集數據，以描述ViviGen的安全性和有效性。
Joseph Park, MD, associate professor and chief of the Foot and Ankle Davison in the Department of Orthopaedic Surgery at UVA, will present findings from his 135-patient retrospective review of ViviGen in high-risk foot and ankle surgeries, showing that patients treated with ViviGen experienced outcomes equivalent to those reported in literature for autograft.
弗吉尼亞大學整形外科副教授兼足部和踝部主任、醫學博士約瑟夫·帕克將發表他對ViviGen在高風險足部和踝部手術中135名患者的回顧性研究結果，結果顯示，接受ViviGen治療的患者經歷的結果與文獻中報道的自體移植相同。
Learn more about LifeNet Health's activities at AAOS, as well as its portfolio of solutions for sports medicine, trauma, extremity and spine procedures, at www.LifeNetHealth.org/AAOS2021.
欲瞭解更多有關LifeNet Health在AAOS的活動及其運動醫學、創傷、四肢和脊柱手術解決方案組合的信息，請訪問www.LifeNetHealth.org/AAOS2021。
About LifeNet Health
LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.
關於LifeNet Health LifeNet Health每年幫助拯救生命、恢復健康，並給成千上萬人帶來希望。它是世界上最值得信賴的移植解決方案提供商-從器官採購到生物植入和細胞療法-也是再生醫學領域的領先者，同時始終向能夠治癒的捐贈者和醫療保健專業人員致敬。有關LifeNet Health的更多信息，請訪問Www.lifenethealth.org.
1. Lareau, et al. Does autogenous bone graft work? A logistic regression analysis of data from 159 papers in the foot and ankle literature. Foot Ankle Surg. 2015;21(3):150-159.
2. Muller, et al. Substitutes of structural and non-structural autologous bone grafts in hindfoot arthrodesis and osteotomies: a systemic review. BMC Musculoskeletal Disorders. 2013;14:59.
1.Lareau等人。自體骨移植有效嗎？足踝文獻159篇數據的Logistic迴歸分析。足踝手術，2015；21(3)：150-159。
2.Muller等人。結構性和非結構性自體骨移植在後足關節融合術和截骨術中的替代物：一項系統綜述。BMC肌肉骨骼疾病。2013年；14：59。
SOURCE LifeNet Health
來源：LifeNet Health
Related Links
相關鏈接
http://www.LifeNetHealth.org
Http://www.LifeNetHealth.org
譯文內容由第三人軟體翻譯。